Ganaplacide
Small moleculeexperimental
Clinical trial activity
10 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
6
Phase 3
1
Phase 4
0
Earliest trial started Mar 1, 2013 (NCT01753323)
Timeline
Indications
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Loading structure…
SMILES
CC1(C)c2nc(-c3ccc(F)cc3)c(Nc3ccc(F)cc3)n2CCN1C(=O)CN- Mol. weight
- 411.46 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2058833 ↗
Also known as
- kaf156
- kaf156
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07235033 | Phase 2 | Jan 23, 2024 | Novartis |
| NCT05750628 | Phase 2 | Dec 26, 2023 | Novartis |
| NCT05842954 | Phase 3 | Dec 11, 2023 | Novartis |
| NCT05330273 | Phase 1 | Apr 28, 2022 | Medicines for Malaria Venture, Novartis |
| NCT05236530 | Phase 1 | Mar 9, 2022 | Medicines for Malaria Venture, Novartis |
| NCT05084651 | Phase 1 | Nov 18, 2021 | Medicines for Malaria Venture, Novartis |
| NCT04546633 | Phase 2 | Oct 22, 2020 | European and Developing Countries Clinical Trials Partnership (EDCTP), Novartis |
| NCT03167242 | Phase 2 | Jul 25, 2017 | Novartis |
| NCT04072302 | Phase 1 | Sep 15, 2014 | Novartis |
| NCT01753323 | Phase 2 | Mar 1, 2013 | Novartis |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 10 | 10 | 3 | 2013 |
| Medicines for Malaria Venture | Academic/Hospital | 3 | 0 | 1 | 2021 |
| European and Developing Countries Clinical Trials Partnership (EDCTP) | Academic/Hospital | 1 | 0 | 1 | 2020 |
3 organizations
Page 1 / 1